-- Pan-Cancer MSI Companion Diagnostic for KEYTRUDA ® (pembrolizumab) Planned for Inclusion on FoundationOne CDx™-- CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 24, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced a collaboration with Merck, known as MSD outside the United States and Canada

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 21, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that under the Protecting Access to Medicare Act of 2014 (PAMA) the Centers for Medicare & Medicaid Services (CMS) approved new Advanced Diagnostic Laboratory Test (ADLT) status for

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2018-- Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the first quarter ended March 31, 2018. Highlights for the quarter included: Posted revenue of $52.8 million, 101% year-over-year growth; Reported 21,861 clinical

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced a comprehensive gene expression profiling (GEP) program to support precision oncology clinical research and development. This initiative, which provides a natural complement to Foundation

--DIAN Designated Roche’s and Foundation Medicine’s Exclusive Clinical Sequencing Partner in China -- -- Roche will Commercialize Foundation Medicine’s Comprehensive Genomic Profiling Tests in China -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 26, 2018-- Foundation Medicine, Inc. , (NASDAQ:FMI), F.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 26, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.S. Food and Drug Administration ( FDA ) granted a Breakthrough Device designation (formerly Expedited Access Pathway program) for its new liquid biopsy assay, which is an expanded

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 17, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's first quarter ended March 31, 2018 will be released on Wednesday, May 2, 2018 . The management team will host a conference call on Wednesday, May 2,

--Data to be Presented at the 2018 Annual Meeting of the American Association for Cancer Research -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 11, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced the presentation of new findings at the American Association for Cancer Research (AACR)

-- FoundationOne CDx is the First Next Generation Sequencing Test for All Solid Tumors to Complete the FDA /CMS Parallel Review Process and Launch with National Medicare Coverage -- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that FoundationOne CDx™,

-- Final NCD Significantly Expands Patient Access Beyond the Preliminary NCD -- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the Centers for Medicare & Medicaid Services (CMS) issued a final National Coverage Determination (NCD) for patients who